Benzinga · Mar 2, 2026
AL
NASDAQ · ALUR
Allurion Technologies Inc.
Healthcare · Medical - Devices
$1.16
Down-$0.09 (-6.90%)
Updated Sep 17, 2026, 12:34 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.09M
- P/E ratio
- -2.1
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 1.2K
- Avg. volume
- 2.57M
Price performance
ALUR price history
1M range · 0 trading sessions · Daily adjusted prices
ALUR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ALUR news
The latest Smart Investors Daily articles mentioning ALUR.
Stock researchCompany · Overview
ALUR research
Overview
Company profile and research snapshot.
Company profile
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 24, 2026 | Chardan Capital | Buy | — |
| Nov 20, 2025 | Chardan Capital | Neutral | — |
| Mar 27, 2025 | Chardan Capital | Neutral | — |
| Mar 21, 2025 | Roth MKM | Buy | — |
| Mar 21, 2025 | Chardan Capital | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Allurion Technologies Plans To Appeal NYSE's Delisting Decision
Allurion Technologies, Inc. (the "Company") (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings
Benzinga · Feb 25, 2026
What's Going On With Allurion Stock On Wednesday?
Allurion shares slipped after it priced a discounted warrant exercise expected to raise about $3 million and add potential dilution.
Fintel · Feb 24, 2026
Chardan Capital Upgrades Allurion Technologies (ALUR)
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
